Entos Pharmaceuticals is a leading brand in the field of genetic personalized medicines, dedicated to revolutionizing healthcare through innovation. With a team of experienced leaders, they are committed to developing next-generation genetic therapies that utilize their pioneering Fusogenix PLV (Nucleic Acid Delivery Platform). Their cutting-edge technology enables the delivery of nanomedicines, promising breakthroughs in the treatment of chronic diseases like cancer and aging.

Heading the team is Dr. John D. Lewis, a renowned scientist and serial entrepreneur who has made significant contributions to cancer therapeutics and imaging-based treatments.

He is the Bird Dogs Chair in Translational Oncology at the University of Alberta. Supporting him is Dr. Arun Raturi, the Chief Scientific Officer, whose expertise lies in the development and validation of the Fusogenix PLV platform.

Dr. Raturi's contributions have resulted in key intellectual property for drug delivery. Dr.

Steve Chen, the Chief Medical Officer, brings his extensive experience in the academic research and pharmaceutical biotechnology sectors to the team. Entos Pharmaceuticals is at the forefront of medical advancements, pushing the limits of personalized medicine to improve patient outcomes and transform the healthcare industry